Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + apatinib in platinum-resistant relapsed ovarian cancer (real-world study)
ChiCTR2100046252Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2100046252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046252.